IOVANCE BIOTHERAPEUTICS, INC. 10-Q

Item 5. Other Information. In July 2020, we entered into a Severance Agreement and General Release with Timothy Morris, our former Chief Financial Officer, effective as of July 8, 2020, pursuant to which Mr. Morris received the severance payment described in Section 6.2 of his Executive Employment Agreement effective August 14, 2017. ​ ​ 80 Table of Contents Item 6. Exhibits EXHIBIT INDEX ​ Exhibit Description 10.1** ​ Severance Agreement and General Release, effective July 8, 2020, between Iovance Biotherapeutics, Inc. and Timothy Morris (incorporated herein by reference to Exhibit 10.4 to the Registrants Quarterly Report on Form 10-Q filed with the Commission on August 6, 2020). 31.1++ Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer. 31.2++ Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer. 32.1++ Section 1350 Certification of Chief Executive Officer (furnished herewith). 32.2++ Section 1350 Certification of Chief Financial Officer (furnished herewith). 101 The following financial information from the Quarterly Report on Form 10-Q of Iovance Biotherapeutics, Inc. for the quarter ended September 30, 2020, formatted in iXBRL (Inline eXtensible Business Reporting Language): (1) Condensed Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019; (2) Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019; (3) Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2020 and 2019; (4) Condensed Consolidated Statements of Stockholders’ Equity as of September 30, 2020 and December 31, 2019; (5) Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019; and (6) Notes to Condensed Consolidated Financial Statements. 104 ​ Cover Page Interactive Data File – the cover page interactive date file does not appear in the Interactive Date File because its XBRL tags are embedded within the Inline XBRL document. ​ ​ ** Certain portions of the Exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. # Indicates a management contract or compensatory plan or arrangement. ++ Filed herewith. ​ ​ ​ 81 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ​ Iovance Biotherapeutics, Inc. November 5, 2020 By: /s/ Maria Fardis, Ph.D., M.B.A. Maria Fardis, Ph.D., M.B.A. Chief Executive Officer (Principal Executive Officer) November 5, 2020 By: /s/ Michael C. Swartzburg Michael C. Swartzburg VP, Finance (Interim Principal Financial Officer) ​ ​ 82